Core Insights - AC Immune SA announced positive interim results from the Phase 2 VacSYn trial for ACI-7104.056, an active immunotherapy targeting alpha-synuclein in early Parkinson's disease, indicating potential to slow disease progression [2][4][11] Interim Results - The VacSYn trial is a placebo-controlled, biomarker-based Phase 2 study involving 34 patients, with all participants treated for at least 12 months [5] - Interim results demonstrated that all target criteria for immunogenicity were met, with a 100% responder rate and a clear safety profile [6][10] - Antibody titers in serum were over 500-fold higher in the treatment group compared to placebo, indicating a robust immune response [7][8] Biomarker and Clinical Assessments - Disease-related biomarkers showed stabilization in the treatment group, including total CSF alpha-synuclein levels and neurofilament light chain (NfL) [12] - Clinical measures indicated a trend for stabilization of motor symptoms in the active treatment group, with no meaningful progression in MDS-UPDRS Part III scores [9][12] Expert Commentary - Dr. Andrea Pfeifer, CEO of AC Immune, emphasized the potential of ACI-7104.056 to transform Parkinson's disease treatment based on the interim data [4] - Dr. Werner Poewe highlighted the promising consistency of trends across multiple biomarkers and clinical assessments, suggesting beneficial effects on disease progression [4] Future Development Plans - Based on the interim results, AC Immune plans to seek regulatory feedback to accelerate the clinical development plan towards registration [11] - Final data from Part 1 of the VacSYn trial is expected in mid-2026 [11]

Chaired by globally renowned nuclear medicine expert Prof. Ken Herrmann, M.D. Other Board members James Cook, Jason Lewis, Ph.D., and Michael Morris, M.D. bring significant clinical and industry expertise, supporting transition from early clinical validation to strategic development ZURICH-SCHLIEREN, Switzerland and CONCORD, Mass., Dec. 11, 2025 (GLOBE NEWSWIRE) -- Molecular Partners AG (SIX: MOLN; NASDAQ: MOLN), a clinical-stage biotech company developing a new class of custom-built protein drugs known as ...

MOUNTAIN VIEW, Calif., Dec. 11, 2025 (GLOBE NEWSWIRE) -- Iridex Corporation (Nasdaq: IRIX), a worldwide leader providing innovative and versatile laser-based medical systems, delivery devices, and accessories for the treatment of glaucoma and retinal diseases, today announced a recently published independent, retrospective study in Ophthalmology and Therapy. The study demonstrates that retreatment of transscleral laser treatment using MicroPulse® technology (MicroPulse TLT) can safely and effectively furthe ...

Data demonstrates the significant and sustained tumor regression achieved by the CAPTN-3 platform across two distinct tri-specific antibodies, IM1240 and IM1305, targeting different tumor antigens Transcriptomic analysis across ~11,000 TCGA samples shows NKG2A expression is strongly associated with tumor expression of 5T4 or TROP2, supporting inclusion of the NKG2A arm in CAPTN-3 designs NKG2A arm significantly contributes to IM1240 anti-cancer immune activity in PD1-resistant patient-derived explants REHOV ...

Core Insights - Lantronix's Edge AI technology has been selected by Trillium Engineering to enhance gimbaled imaging systems for military and commercial unmanned aircraft, showcasing its compliance with NDAA/TAA standards [1][2] Industry Overview - The global drone market is projected to reach $57.8 billion by 2030, indicating significant growth potential for companies like Lantronix that provide advanced connectivity solutions [2] - The collaboration with Trillium Engineering positions Lantronix as a key player in defense and intelligence technology innovation, capitalizing on the increasing demand for mission-critical edge computing [2][3] Strategic Significance - The partnership with Trillium Engineering highlights Lantronix's capability to deliver AI-powered edge computing solutions, creating long-term recurring revenue opportunities in both defense and commercial sectors [3][6] - Trillium's systems are utilized in various applications, including intelligence, surveillance, reconnaissance (ISR), infrastructure inspection, and wildland fire operations, further expanding Lantronix's market reach [3][6] Technology Advantage - Lantronix's Open-Q 5165RB System on Module (SOM), powered by Qualcomm® Dragonwing™ processors, enables advanced on-device AI capabilities for Trillium's products, enhancing operational efficiency and real-time intelligence [5][7] - The technology supports features such as real-time edge AI processing, AI object detection and tracking, and precision targeting with low latency, making it suitable for compact, power-efficient uncrewed platforms [7][8] Investor Insights - The collaboration with Trillium Engineering is a strategic move for Lantronix to drive sustainable, high-margin growth through differentiated Edge AI solutions, particularly in the robust drone and defense markets [5][6] - By expanding its footprint in high-growth sectors characterized by long product lifecycles, Lantronix aims to capture additional recurring revenue opportunities and strengthen its competitive position in the global IoT and AI ecosystem [5][6]

BOSTON and LONDON, Dec. 11, 2025 (GLOBE NEWSWIRE) -- Centessa Pharmaceuticals plc (Nasdaq: CNTA), a clinical-stage pharmaceutical company, today announced that its Board of Directors has appointed Mario Alberto Accardi PhD, President and founder of Centessa’s Orexin Program, as Chief Executive Officer (CEO) and member of the Board, effective January 1, 2026. Dr. Accardi will succeed Saurabh Saha MD PhD, who will step down from his position as CEO and a member of the Board, effective January 1, 2026. Dr. Sah ...

In DUBLIN-3 non-squamous EGFR WT NSCLC patients who progressed after anti-PD-(L)1, Plinabulin + docetaxel showed consistent and clinically meaningful improvements in OS, PFS, and ORR, reinforcing Plinabulin as a late-stage therapy with consistent survival benefit in anti-PD-(L)1-progressed NSCLC patients. Supported by anti-cancer efficacy and safety in significant reduction exposure-adjusted grade 3/4 adverse events in DUBLIN-3, BeyondSpring will conduct DUBLIN-4, a global, double-blind Phase 3 registration ...

Core Insights - The Lovesac Company reported a slight increase in net sales of 0.2% to $150.2 million for Q3 FY26 compared to Q3 FY25, driven primarily by showroom growth despite a decline in omni-channel comparable net sales [1][8]. Financial Performance - Net sales for the thirteen weeks ended November 2, 2025, were $150.2 million, a 0.2% increase from $149.9 million in the prior year [3]. - Showroom sales increased by 12.8% to $102.7 million, while internet sales decreased by 16.9% to $37.3 million [3]. - Gross profit decreased by 3.9% to $84.2 million, with a gross margin of 56.1%, down from 58.5% in the prior year [3][8]. - Total operating expenses rose by 4.9% to $100.0 million, with SG&A expenses increasing by 4.5% to $75.0 million [3][8]. - The company reported a net loss of $10.6 million, or $(0.72) per share, compared to a net loss of $4.9 million, or $(0.32) per share, in the prior year [3][8]. Year-to-Date Performance - For the thirty-nine weeks ended November 2, 2025, net sales increased by 2.3% to $449.1 million, driven by a 0.4% increase in omni-channel comparable net sales and the addition of 17 new showrooms [8]. - Gross profit for the year-to-date period decreased by 1.1% to $249.2 million, with a gross margin of 55.5% [8]. - The year-to-date net loss was $28.0 million, or $(1.91) per diluted share, compared to a net loss of $23.8 million, or $(1.53) per diluted share, in the prior year [8][13]. Strategic Initiatives - The CEO emphasized a focus on growth initiatives, including new product launches and marketing evolution, aiming for three million Lovesac households by 2030 [2]. - The company opened five new showrooms during Q3 FY26, maintaining a total of 275 showrooms [5][8]. Cash Flow and Inventory - As of November 2, 2025, cash and cash equivalents were $23.7 million, down from $61.7 million a year earlier [13]. - Total merchandise inventory increased to $129.7 million, primarily due to increased freight capitalization and planned stock inventory increases [13].

NEW YORK and AMSTERDAM, Dec. 11, 2025 (GLOBE NEWSWIRE) -- Atai Beckley N.V. (NASDAQ: ATAI) (“AtaiBeckley” or the “Company”), a clinical-stage biopharmaceutical company on a mission to transform patient outcomes by developing effective, rapid-acting and convenient mental health treatments, today announced that the United States Patent and Trademark Office has granted a new patent covering EMP-01 (oral R-MDMA), further strengthening the company’s intellectual property estate and long-term exclusivity for the ...

Project will test the use of plasma in the recovery of critical minerals from end-of-life batteriesMONTREAL, Dec. 11, 2025 (GLOBE NEWSWIRE) -- PyroGenesis Inc. (“PyroGenesis”) (TSX: PYR) (OTCQX: PYRGF) (FRA: 8PY1), the leader in ultra-high temperature processes and engineering innovation, and a plasma-based technology provider to heavy industry & defense, announces today the recent signing of a contract with a company engaged in large-scale battery recycling, for the testing of high-temperature plasma durin ...